Thomas Klein
Thomas Klein is Founder & CEO at PIRCHE AG. He is an entrepreneur, who starts and runs companies with a strong technological base. In 2015 Thomas Klein started the digital diagnostic platform Pirche and have since served as its CEO. In 2004 he was the co-founder of Arcway, the first spin-off from the Hasso-Plattner Institute in Potsdam and served as its chairman until it was sold in 2010. From 2006 – 2020 he was the business development advisor and legal representative for all clinical trials in Europe of Pluristem (NASDAQ:PSTI). From 1997 to 2006, he was co-founder and CEO of Noxxon Pharma AG and exited when Pfizer invested in Noxxon.

Olivier Litzka
Olivier Litzka has been a partner at Andera Partners since 2006, helping establish Andera Life Sciences as a leading European fund in biotech and medtech. He began his career at Mercer Management Consulting in 1998 before joining 3i Group in 2000, focusing on biopharma and medtech investments. Litzka serves on the boards of multiple companies, including MMI Microsystems, T-Knife, and HighLife Medical, and previously held board positions at firms acquired or taken public. He holds a Ph.D. in molecular microbiology from the Institut für Genetik und Mikrobiologie in Munich.

Ulrich Kinzel
Ulrich Kinzel Partner and Head of Healthcare Europe at Bryan, Garnier & Co. Bryan Garnier is the leading European Growth Investment Bank and recently announced that it is joining forces with Stifel. Kinzel is an experienced senior corporate finance professional and managed more than 60 successful M&A and ECM transactions, including cross-border European, Asian and US public and private takeovers as well as IPOs and secondary offerings on all major European Stock Exchanges. Kinzel joined Bryan Garnier from goetzpartners, now Fortlane Partners, where he built a pan-European advisory business in the pharmaceutical and healthcare sector over a decade and led the corresponding teams in Munich and London.

Elena Lovo 
Elena Lovo is an Executive Director in the Healthcare Investment Banking group at JP Morgan where she works with Biotech clients in Europe. During her 6 years in banking, she has been supporting several companies in their strategic and capital formation journey. Before moving into banking, Elena worked in strategy consulting and in transaction advisory, mainly supporting pharma and biotech clients on product licensing and M&A transactions. Elena received a PhD in Immunology from Imperial College London, spent some time working in Prof R. Gallo’s lab at the Institute of Human Virology in Baltimore, MD, and has Masters of Science in Medical Biotechnologies from San Raffaele University in Milan.